Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B

Intervirology

Volumn 48, Issue 6, 2005, Pages 381-388

  Nakanishi, Hiroyuki ^a   Kurosaki, Masayuki ^a   Asahina, Yasuhiro ^a   Onuki, Yuko ^a   Ueda, Ken ^a   Nishimura, Yuki ^a   Tsuchiya, Kaoru ^a   Kitamura, Takatoshi ^a   Uchihara, Masakatsu ^a   Miyake, Shozo ^a   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Breakthrough hepatitis; Domain B; Hepatitis B virus DNA; INNO LiPA; Lamivudine

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RELAPSE; STRUCTURAL GENE; TREATMENT OUTCOME;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREDICTIVE VALUE OF TESTS; PROTEIN STRUCTURE, TERTIARY; RECURRENCE; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 22344451100     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086065     Document Type: Article

References (45)

1. Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2001;120:1828-1853.
2. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
3. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-748.
4. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
5. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
6. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
7. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H: Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003;46:164-170.
8. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9399.
9. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
10. Chien RN, Liaw YF: Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology 2003;46:362-366.
11. Yotsuyanagi H, Yasuda K, lino S: Short-term lamivudine for the treatment of chronic hepatitis B. Intervirology 2003;46:367-372.
12. Lok AS, McMahon BJ: Chronic hepatitis B: Update of recommendations. Hepatology 2004;39:857-861.
13. Chayama K, Suzuki Y, Kobayaski M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
14. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-568.
15. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
16. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS: Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34:583-589.
17. Zollner B, Schafer P, Feucht HH, Schroter M, Petersen J, Laufs R: Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-663.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
19. Honkoop P, de Man RA, Niesters HG, Schalm SW: Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 1998;29:510-511.
20. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY: Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate- aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-405.
21. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH: Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
22. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001;34:590-594.
23. Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559.
24. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S: A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218-223.
25. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
26. Sakugawa H, Kobashigawa K, Nakayoshi T, Yamashiro T, Maeshiro T, Tomimori K, Kinjo F, Saito A, Mukaide M: Monitoring low level hepatitis B virus by a newly developed sensitive test. Hepatol Res 2003;26:281-286.
27. Kurosaki M, Enomoto N, Asahina Y, Sakuma I, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C: Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996;49:115-123.
28. Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S: Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol 2003;39:1063-1069.
29. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R: Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-707.
30. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E: Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-3734.
31. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
32. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088.
33. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
34. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, TurKaspa R: Genotypic and phenotypic resistance: Longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159.
35. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Matsuda M, Satoh J, Takagi K, Kumada H: Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003;46:182-189.
36. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B: Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004;39:64-73.
37. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, Heinz FX, Watschinger B, Hofmann H: Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-2066.
38. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Saitoh S, Arase Y, Ikeda K, Kumada H: The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003;38:315-321.
39. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P: Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
40. Gunther S, Fischer L, Pult I, Sterneck M, Will H: Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137.
41. Poch O, Sauvaget I, Delarue M, Tordo N: Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989;8:3867-3874.
42. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, et al: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993;90:6320-6324.
43. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
44. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455.
45. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975.